

Amendments to the Specification:

On page 3, please amend the paragraph starting on line 13 as follows:

- - In patients with this disease, an immunoglobulin fraction can be isolated from the plasma, containing auto-antibodies which bind onto the angiotensin-1 receptor and activate the cell via it. If peptides of the AT₁ receptor portraying the point of binding for the antibodies are added to the cell culture system - in vitro -, the pathological effect of the auto-antibodies can be annulled. Similar things are possible by using peptides with analog functions, preferably with the amino-acid sequence AFHYESQ (SEQ ID NO: 1), AVHYQSN (SEQ ID NO: 2), SHFYQTR (SEQ ID NO: 3), GYYFDTN (SEQ ID NO: 4), ENTNIT (SEQ ID NO: 5). - -

On page 4, please amend the paragraph starting on line 1 as follows:

-- It was surprisingly established that the antibodies recognise an epitope on the second extra-cellular loop of the AT₁ receptor and that they can be neutralised and affinity-chromatographically cleaned with the help of peptides corresponding to this loop. The epitope is characterised by the amino-acid sequence AFHYESQ (SEQ ID NO: 1). Further, function-analog peptides with the amino-acid sequence AVHYQSN (SEQ ID NO: 2), SHFYQTR (SEQ ID NO: 3), GYYFDTN (SEQ ID NO: 4) or ENTNIT (SEQ ID NO: 5) are part of the scope of the invention. --

On page 4, please amend the paragraph starting on line 11 as follows:

-- Peptides partially or totally containing SEQ ID NO: 1 ~~no. 1~~ (AFHYESQ) are preferred.-
-

On page 4, please amend the paragraph starting on line 14 as follows:

-- Antibodies according to the invention aimed against the epitope of the AT₁ receptor

are characterised by the fact that they recognise these peptides. Preferably, they recognise the peptide of SEQ ID NO: 1 ~~no. 1~~ (AFHYESQ) or its variants. Further antibodies recognise the peptides with the amino-acid sequence AVHYQSN (SEQ ID NO: 2), SHFYQTR (SEQ ID NO: 3), GYYFDTN (SEQ ID NO: 4) or ENTNIT (SEQ ID NO: 5). They are produced with methods known per se by immunisation of small mammals or immunisation of spleen cells in vitro with the peptides according to the invention. --

On page 4, please amend the paragraph starting on line 23 as follows:

-- Further, the invention relates to antigenic agents for detection of preeclampsia, containing at least one peptide according to the invention, preferably the peptide of SEQ ID NO: 1 ~~no. 1~~ (AFHYESQ), or also peptides with the amino-acid sequence AVHYQSN (SEQ ID NO: 2), SHFYQTR (SEQ ID NO: 3), GYYFDTN (SEQ ID NO: 4), ENTNIT (SEQ ID NO: 5). They react with the specific antibodies against blood-pressure-effective angiotensin-AT₁ receptors occurring in preeclampsia. If need be, the antigenic agents are bound to various carriers, such as activated sepharose, cellulose or polystyrene carriers. --

On page 4, please amend the paragraph starting on line 30 as follows:

-- A further use of the peptides according to the invention entails immunogenic agents. These contain at least one peptide, preferably the peptide of SEQ ID NO: 1 ~~no. 1~~ (AFHYESQ), or also peptides with the amino-acid sequence AVHYQSN (SEQ ID NO: 2), SHFYQTR (SEQ ID NO: 3), GYYFDTN (SEQ ID NO: 4), ENTNIT (SEQ ID NO: 5), which induce the production of antibodies capable of recognising auto-anti-gens in preeclampsia. --

On page 6, please amend the paragraph starting on line 13 as follows:

-- The specific immunoglobulin adsorption is done on a column on which there are peptides in which at least the antibody-binding sequence AFHYESQ (SEQ ID NO: 1) is contained (preferably containing the second extra-cellular loop of the AT₁ receptor or ~~sequence ID no. 1~~ SEQ ID NO: 1). - -